Pharmacotherapy for post traumatic stress disorder (PTSD)

Area of Science:

• Psychiatry and Mental Health
• Pharmacology
• Clinical Trials

Background:

• Posttraumatic stress disorder (PTSD) is a common and debilitating condition.
• Psychobiological dysfunctions in PTSD have spurred interest in pharmacotherapy.
• Medication plays a growing role in managing PTSD symptoms.

Purpose of the Study:

• To evaluate the efficacy of various medications in reducing PTSD symptoms in adults.
• To assess the overall impact of pharmacotherapy on PTSD treatment response.
• To identify first-line medication classes for PTSD management.

Main Methods:

• Systematic review and meta-analysis of randomized controlled trials (RCTs).
• Searched major databases including CENTRAL, MEDLINE, Embase, PsycINFO, and PTSDPubs.
• Included 66 RCTs with 7442 participants; 54 used in meta-analysis.

Main Results:

• Selective serotonin reuptake inhibitors (SSRIs) demonstrated a significant beneficial effect compared to placebo (RR 0.66, moderate-certainty evidence).
• Mirtazapine (NaSSA) and amitriptyline (TCA) showed potential benefits, but with low-certainty evidence.
• Antipsychotics showed no evidence of benefit (very low-certainty evidence); SSRIs were associated with increased withdrawal rates, though absolute dropout due to adverse events was low.

Conclusions:

• SSRIs are recommended as first-line pharmacotherapy for PTSD due to moderate-certainty evidence of symptom improvement.
• Mirtazapine and amitriptyline may offer benefits, but require further investigation due to low-certainty evidence.
• Further research is needed to identify more effective PTSD treatments, addressing current evidence gaps.